HK Stock MarketDetailed Quotes

FOSUN PHARMA (02196)

Watchlist
  • 18.840
  • +0.020+0.11%
Trading May 6 10:06 CST
50.10BMarket Cap12.72P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

FOSUN PHARMA (02196) Revenue Breakdown Overview

By Business/Source

Currency:CNY
2025/FY
Stock NameRevenueRatio
Pharmacy29.68B71.53%
Medical and health services7.37B17.75%
Medical devices and medical diagnosis4.32B10.40%
Other131.37M0.32%

By Product

Currency:CNY
2025/FY
Stock NameRevenueRatio
Pharmacy29.68B71.53%
Medical and health services7.37B17.75%
Medical devices and medical diagnosis4.32B10.40%
Other131.37M0.32%

By Country/Region

Currency:CNY
2025/FY
Stock NameRevenueRatio
China Mainland28.52B68.73%
Other regions and countries12.98B31.27%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +6.96%
Sample Name
Sample Code
 +4.80%
Sample Name
Sample Code
 +3.86%
4
CNOOC
00883
+1.55%
5
SINOPEC CORP
00386
+1.53%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +54.80%
Sample Name
Sample Code
 +51.07%
Sample Name
Sample Code
 +48.04%
4
Business-intelligence Of Oriental Nations Corporation
300166
+32.54%
5
Emdoor Information
001314
+32.54%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -